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2-Arachidonoylglycerol (2-AG) is the most potent endogenous ligand of brain cannabinoid
CB1 receptors and is synthesized on demand from 2-arachidonate-containing phosphoinosi-
tides by the action of diacylglycerol lipase in response to increased intracellular calcium.
Several studies indicate that the endocannabinoid (eCB) system is involved in the mecha-
nism of reward and that diverse drugs of abuse increase brain eCB levels. In addition, eCB
are self-administered (SA) by squirrel monkeys, and anandamide increases nucleus accum-
bens (NAc) shell dopamine (DA) in rats. To date, there is no evidence on the reinforcing
effects of 2-AG and its effects on DA transmission in rodents. In order to fill this gap, we
studied intravenous 2-AG SA and monitored the effect of 2-AG on extracellular DA in the
NAc shell and core via microdialysis in male Sprague-Dawley rats. Rats were implanted
with jugular catheters and trained to self-administer 2-AG [25 mg/kg/inf intravenously (iv)]
in single daily 1 h sessions for 5 weeks under initial fixed ratio (FR) 1 schedule. The ratio
was subsequently increased to FR2. Active nose poking increased from the 6th SA session
(acquisition phase) but no significant increase of nose pokes was observed after FR2.When
2-AG was substituted for vehicle (25th SA session, extinction phase), rate responding as
well as number of injections slowly decreased. When vehicle was replaced with 2-AG, SA
behavior immediately recovered (reacquisition phase). The reinforcing effects of 2-AG in
SA behavior were fully blocked by the CB1 receptor inverse agonist/antagonist rimona-
bant (1 mg/kg intraperitoneally, 30 min before SA session). In the microdialysis studies, we
observed that 2-AG (0.1–1.0 mg/kg iv) preferentially stimulates NAc shell as compared to
the NAc core. NAc shell DA increased by about 25% over basal value at the highest doses
tested (0.5 and 1.0 mg/kg iv). The results obtained suggest that the eCB system, via 2-AG,
plays an important role in reward.
Keywords: endocannabinoids, 2-arachidonoilglycerol, self-administration, reward, drug addiction, in vivo
microdialysis, nucleus accumbens
INTRODUCTION
Endocannabinoid (eCB) signaling controls various central func-
tions in mammals, such as nociception, feeding, energy home-
ostasis, mood, learning, memory, growth, development, and
reward processes (1–6). The eCB system consists of cannabinoid
receptors (CB1 and CB2), lipid-derived endogenous ligands [N -
arachidonoylethanolamine or anandamide,2-arachidonoylglycerol
Abbreviations: 2-AG 2-arachidonoylglycerol; DA, dopamine; eCB, endocannabi-
noids; HPLC, high performance liquid chromatography; HPLC–MS/MS, high
performance liquid chromatography–mass spectrometry; ip, intraperitoneally; iv,
intravenously NAc, nucleus accumbens; SA, self-administration.
(2-AG)], and specific enzymes involved in the biosynthesis and
degradation of eCB.
Many questions on eCB signaling still need to be answered.
However, among the two endogenous ligands, anandamide and
2-AG, 2-AG appears to be the most potent endogenous ligand for
brain cannabinoid CB1 receptors (7). 2-AG acts as a full agonist
of CB1 and CB2 receptors (8–10), and is synthesized on demand
from 2-arachidonate-containing phosphoinositides by the action
of diacylglycerol lipase (DAGLα and DAGLβ) in response to ele-
vations of intracellular calcium. Unlike classic neurotransmission
systems (e.g., monoaminergic, cholinergic, aminoacidergic), 2-
AG signaling in the nervous system takes place in a retrograde
fashion. Thus, stimulation of the postsynaptic neuron induces
www.frontiersin.org October 2014 | Volume 5 | Article 140 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De Luca et al. Endocannabinoid system and drug addiction
the biosynthesis of 2-AG that thus diffuses to the presynaptic
terminal to act on CB1 receptors; due to its lipophilic nature,
no synaptic vesicles for storage of 2-AG exist (4, 11, 12). Given
these characteristics, 2-AG is considered to be a neuromodulator
rather than a transmitter. CB1 activation of Gi/o proteins inhibits
neurotransmission but the net inhibitory or excitatory effect of
2-AG signaling depends on the type of neurons involved in the
process (4, 13–16). 2-AG is mainly degraded by monoacylglycerol
lipase (MAGL), a membrane-associated, cytoplasm-facing solu-
ble enzyme located pre-synaptically at axon terminals along with
the CB1 receptor (17–19). Furthermore, about 15% of 2-AG is
hydrolyzed by ABHD6 and ABHD12, and the remaining 1–2%
by fatty acid amide hydrolase (FAAH) (20). The mechanisms of
2-AG neuronal reuptake are not completely known, but putative
transporters have been described (3, 21).
Drugs of abuse affect brain eCB levels and it has been proposed
that the activation of the eCB system is involved in many aspects
of addiction (22). Drug-induced increases in eCB synthesis play
a role in drug reward, and it has been suggested that eCBs are
involved in long-term synaptic plasticity of neural substrates of
motivation and reward in relation to addiction (23).
In human beings, a genetic disruption of eCB clearance is asso-
ciated with drug abuse (24, 25). CB1 receptor activation affects
the addictive properties of opioids, cocaine, alcohol, and nicotine
(26). On the other hand, CB1 KO mice show reduced ethanol
and morphine self-administration (SA) and attenuated ethanol-
and opiate-induced place conditioning (27–29). In rats, the CB1
receptor inverse agonist/antagonist SR-141716A (Rimonabant)
reduces ethanol and opiate SA (30–32) while in mice it reverses
the behavioral and neurochemical effects of cocaine (33).
∆9-Tetrahydrocannabinol (THC), the main active component
of marijuana, is known to reduce the severity of opioid withdrawal
in human beings and rodents, and acute inhibition of FAAH or
MAGL alleviates symptoms of precipitated and spontaneous with-
drawal in opioid- and THC-dependent mice (34, 35). The eCB
system is involved in the rewarding effects of THC (22), as well as
ethanol and opiates (36, 37). In particular, ethanol and heroin SA
increases eCB levels in the nucleus accumbens (NAc) shell, sug-
gesting a role for NAc eCB transmission in the reinforcing effects
produced by these drugs (38). Finally, eCBs are SA by squirrel mon-
keys, meaning that they are effective reinforcers of drug-taking
behavior (39, 40).
Dopamine (DA) neurotransmission is known to regulate a large
number of motivated and addiction-related behaviors (41–43).
Importantly, drugs of abuse of the most diverse pharmacologi-
cal classes increase mesolimbic DA transmission in rats as well
as in human beings preferentially or, depending on doses and
conditions, selectively in the ventral striatum/NAc (42, 44–48).
Accordingly, THC and the synthetic cannabinoid WIN 55,212-
2 increase extracellular DA concentrations in the shell, but not
in the core of the NAc, both when injected intravenously (iv)
(49) and when SA by different strains of rats (50, 51). In
addition, anandamide increases NAc shell DA and its effect is
amplified by the FAAH inhibitor, URB597 (52). On the other
hand, reduced DA transmission in the mesolimbic system is
associated with spontaneous or rimonabant-precipitated THC
withdrawal (53, 54).
In spite of this extensive literature, no studies are available on
the reinforcing effects of 2-AG and its effects on DA transmis-
sion in rodents. In order to fill this gap, we studied intravenous
2-AG SA and monitored the effect of 2-AG on extracellular DA in
the NAc shell and core via microdialysis in male Sprague-Dawley
rats.
MATERIALS AND METHODS
ANIMALS
Male Sprague-Dawley rats (Harlan, Italy), weighting 250–275 g
upon arrival, were housed four per cage given ad libitum access to
food and water in a temperature (22°C) and humidity (60%) con-
trolled vivarium with a 12 h light/dark cycle (on 08:00 A.M., off
08:00 P.M.). After surgery (catheter implantation), rats were indi-
vidually housed in plastic cages (30 cm× 20 cm× 20 cm) given
ad libitum food and water access, and in the same environmen-
tal conditions. For 7–10 days before surgery, rats were handled
twice a day. SA sessions were performed during the light phase,
between 9:00 a.m. and 5:00 p.m. After the experimental ses-
sions, the rats were returned to their home cages where a daily
ration of 18 g of food was made available, which maintained body
weights at stable levels throughout these studies. The weight of
rats at the beginning of SA studies was 300–325 g. Rats were
weighed every day for the duration of the SA experiments. No
significant reduction of body weight was observed. All experi-
mental procedures met the guidelines and protocols approved by
Italian (D.L. 116/92 and 152/06) and European Council direc-
tives (609/86 and 63/2010) and in compliance with the approved
animal policies by the Ethical Committee for Animal Experi-
ments (CESA, University of Cagliari) and the Italian Ministry of
Health.
DRUGS
The eCB 2-AG was purchased from Tocris Cookson Ltd. (North-
point, UK) and was dissolved in a vehicle containing 2% ethanol,
2% Tween 80, and saline and administered as an intravenous bolus
of 20µl for SA studies (12.5, 20, 50µg/kg/infusion) or 1 ml/kg
solution for microdialysis studies (0.1–1 mg/kg iv).
The CB1 receptor inverse agonist/antagonist rimonabant (SR-
141716A) was obtained from Sigma (RD-Sigma, Italy) and sus-
pended in 0.3% Tween 80 and saline. It was administered (1 mg/kg
intraperitoneally, ip) 30 min prior to 2-AG SA sessions.
2-AG SOLUTIONS
2-Arachidonoylglycerol content in the solutions prepared for SA
or microdialysis studies was determined by HPLC–MS/MS analy-
sis performed on MAX-RP C18 column (150× 4.60 mm; 4µm).
The samples (20 µL) were analyzed by ESI in positive SIM mode
following the ion [M+H]+ 379 m/z. The HPLC conditions were
as follows: flow rate: 0.4 ml/min; solvent A: 0.1% formic acid in
water; solvent B: acetonitrile; and gradient: solvent B 5–100% over
10 min. The samples (20µl) were then analyzed by a Varian 1200
triple quadrupole HPLC–MS. Mass spectral data were acquired
with a scan time of 1.0 s, needle 3500 V, shield 600 V, capillary 30 V,
and detector 1900 V. The source parameters were adjusted as fol-
lows: drying gas temperature 250°C, drying gas pressure 20 psi,
and nebulizer pressure 45 psi.
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SELF-ADMINISTRATION STUDIES
Daily SA sessions were carried out in chambers housed in sound-
proof boxes (Coulbourn Instruments, Allentown, NJ, USA) con-
taining two nose-poke holes, one active and the other inactive. A
yellow/green light was placed over the active hole and a red light
over the inactive one as discriminative stimuli. Prior to each daily
session, the jugular catheter was flushed with 0.1 ml of sterile saline
and the rats were placed in the SA box.
Rats were anesthetized with Equitesin (3 ml/kg ip; chlo-
ral hydrate 2.1 g, sodium pentobarbital 0.46 g, MgSO4 1.06 g,
propylene glycol 21.4 ml, ethanol (90%) 5.7 ml, H2O 3 ml) and
implanted in the right jugular vein with a catheter, consisting of
medical-grade tubing (Silastic, Dow Corning Corporation, Michi-
gan, USA) according to the technique previously described (50). A
stable fixation in the mid-scapular region of the back was embed-
ded by a polypropylene mesh (Evolution, BULEV, weight 48 g/mq,
Dipromed, Italy). During the recovery period, at least 7 days after
surgery, the catheters were flushed daily with 0.1 ml of gentam-
icin (40 mg/ml) and with heparinized saline (heparin 250 U/ml in
0.9% sterile saline).
Ten days after recovery from surgery, 13 rats were trained to
SA 2-AG (25µg/kg/20µl, iv) in 1 h-daily sessions (5 days/week)
for 13 consecutive sessions, according to a FR 1 schedule of rein-
forcement (FR 1, 1 nose poke: 1 injection). During the third week,
when all rats had fulfilled the criterion of 85% responses in the
active hole and stable responding over three sessions, the schedule
of reinforcement was increased to FR 2 (2:1) (14th–24th session).
A nose poke in the active hole resulted in a 4-s infusion of 2-AG.
Each 2-AG infusion was followed by a 20-s time-out period, dur-
ing which further nose pokes were recorded but did not result
in additional intravenous infusions. Rats were also studied in the
extinction phase from the 25th session, when the 2-AG solution
was substituted with vehicle (25th–32nd day of administration).
A group of six rats were also studied in reacquisition when vehicle
was replaced with 2-AG (33th–40th). Another group of animals
were used to study the effect of varying injection doses of 2-AG.
At the end of each SA session, the catheters were flushed with
0.1 ml of heparinized saline. The responses performed by each rat
on both holes for the entire 1-h daily session and the correspond-
ing number of reinforces received was recorded (Graphic State 2
software, Coulbourn instruments, PA, USA).
MICRODIALYSIS STUDIES
Rats were anesthetized with Equitesin (3 ml/kg ip), prepared as
previously described, and placed in a stereotaxic apparatus. The
skull was exposed, and a small hole was drilled on one side. The
probe was implanted vertically in the NAc shell (A+ 2.2; L+ 1.0
from bregma;V-7.8 from dura) or in the NAc core (A+ 1.4; L+ 1.6
from bregma; V-7.6 from dura) according Paxinos and Watson
(55), and then fixed on the skull with dental cement. Rats were
housed in transparent plastic (Plexiglas) hemispheric bowls with
food and water available. Experiments were performed on freely
moving rats 24 h after probe implantation. A Ringer’s solution
(147 mM, NaCl; 2.2 mM, CaCl2; 4 mM, KCl) was pumped through
the dialysis probe at a constant rate of 1µl/min. Dialysate samples
(10µl) were taken every 10 min and injected without purifica-
tion into an HPLC apparatus equipped with a reverse-phase col-
umn (C8 3.5µm, Waters, Mildford, MA, USA) and a coulometric
detector (ESA Coulochem II, Bedford, MA, USA) to quantify DA.
The first electrode of the detector was set at+ 130 mV (oxida-
tion) and the second at −175 mV (reduction). The composition
of the mobile phase was 50 mM NaH2PO4, 0.1 mM Na2-EDTA,
0.5 mM n-octyl sodium sulfate, and 15% (v/v) methanol, pH 5.5.
The sensitivity of the assay for DA was 5 fmol/sample.
At the end of the experiment, animals were sacrificed and their
brains were removed and stored in formalin (8%) before histolog-
ical analysis. To this end, brains were cut on a vibratome in serial
coronal slices (20µm) oriented according to Paxinos and Watson
(55) to locate the placement of the microdialysis probe.
DATA ANALYSIS
Nose pokes emitted during each 1-h 2-AG SA session during acqui-
sition and extinction phases were analyzed by two-way repeated
measures ANOVA with nose pokes (i.e., active vs inactive) and days
as within subject factors. Reacquisition was analyzed by two-way
ANOVA, with nose pokes (i.e., active vs inactive) and days with
respect to the corresponding final 2-AG session (i.e., 32nd 2-AG
SA session) as within subject factors. Where significant effects were
obtained by ANOVA; LSD post hoc tests were performed.
Repeated measures ANOVA was applied to the data obtained
from the serial assays of DA after each treatment. Results from
treatments showing significant overall changes were subjected
to post hoc Tukey tests with significance for p< 0.05. Basal val-
ues were the means of three consecutive samples differing less
than 10%.
RESULTS
SELF-ADMINISTRATION STUDIES
Experiment 1: acquisition, extinction, and reacquisition of 2-AG
self-administration
In this experiment, acquisition, extinction, and reacquisition of
2-AG SA were studied. Figure 1A shows that rats implanted with a
jugular catheter were trained to SA 2-AG (25µg/kg/20µl infusion,
unit dose) in a single daily 1 h session, under an initial FR (FR) 1
schedule, which was then increased to FR2. Figure 1A also shows
the average number of active and inactive nose pokes performed by
rats trained on 2-AG SA during acquisition, extinction, and reac-
quisition phases. Two-way ANOVA of acquisition and extinction
phases showed a significant effect of nose pokes (F1,24= 3.466;
p< 0.0001), and of sessions (F31,744= 182.97; p< 0.0001) and
a significant nose pokes × session interaction (F31,744= 214.069;
p< 0.0001). LSD post hoc tests showed significant differences
between active vs inactive nose pokes from the 7th to the 29th
2-AG SA session. Two-way ANOVA of reacquisition, applied from
the period 32nd to 40th session, showed a main effect of active
vs passive nose pokes (F1,10= 1381.47; p< 0.01). LSD post hoc
tests showed significant differences between active and inactive
nose pokes from the 33rd to the 40th 2-AG SA session. No dif-
ferences were observed in active nose poking on each Monday
following the weekend abstinence compared with the last session
of the preceding week. The percentage of rats that acquired 2-AG
SA was 90%.
Figure 1B shows the daily intake (µg/kg) of 2-AG or vehicle
during all phases of SA (leftY -axis) and the corresponding number
of reinforcements obtained (right Y -axis) in each 1-h session
under a FR 1 or FR 2 schedule from rats that acquired 2-AG SA.
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FIGURE 1 | Acquisition, extinction, and reacquisition of 2-AG
self-administration (SA) behavior over consecutive session.
(A) Number of responses (nose pokes) for 2-AG SA (25 µg/kg/infusion).
Results are expressed as mean±SEM of nose pokes in the active (circle)
and inactive (triangle) holes during each 1-h daily session under FR 1 and FR
2 schedule (acquisition phase: 1st–24th days, filled symbols, N =13;
extinction phase: 25st–32nd days, open symbols, N =13; reacquisition
phase: 33th–40th days, filled symbols; N = 6). *p<0.05 vs inactive nose
pokes; ANOVA followed by LSD post hoc test. (B) Daily intake and number
of infusions during 2-AG SA. Data are expressed as µg/kg (leftY -axis) or
number of infusions (rightY -axis) of 2-AG during each 1-h daily session
(1st–24th; 33th–40th, filled squares) or vehicle (25th–32nd, open squares).
(C) Number of responses during each phase of 2-AG SA. Each bar
represents the mean±SEM of the last three sessions under acquisition,
extinction, and reacquisition phases of 2-AG SA. *p<0.05 vs acq.;
#p<0.05 vs reacq. ANOVA followed by LSD post hoc test.
Figure 1C shows the mean number of responses during the
last three sessions of acquisition, extinction, and reacquisition
phases. One-way ANOVA showed a main effect of the different
SA phases (F2,15= 7.81; p< 0.05). LSD post hoc tests showed
significant differences between extinction and acquisition or
reacquisition.
Experiment 2: effect of dose of 2-AG and CB1 receptor blockade on
2-AG SA
In the second experiment, the effects of varying doses of 2-
AG (12.5–50µg/kg/20µl infusion, unit dose) and rimonabant
(SR-141716A, 1 mg/kg ip, 30 min before SA session) under an
FR1 schedule were studied (Figures 2A,B). Two-way ANOVA
of acquisition at the dose of 25µg/kg/infusion showed a sig-
nificant effect of nose pokes (F1,24= 3.896; p< 0.0001) and of
sessions (F15,360= 324.115; p< 0.0001), and a significant nose
poke × session interaction (F15,360= 316.965; p< 0.0001). LSD
post hoc tests showed significant differences between active and
inactive nose pokes (7, 10, 12, 13, and 15th SA session). Two-
way ANOVA of acquisition at the dose of 12.5µg/kg/infusion
showed a main effect of active vs passive nose pokes (F1,15= 1.45,
p< 0.001). LSD post hoc tests showed significant differences
between active and inactive nose pokes (18, 20th 2-AG SA session).
Two-way ANOVA of acquisition at the dose of 50µg/kg/infusion
showed a main effect of active vs passive nose pokes (F1,15= 8.25;
p< 0.01). LSD post hoc tests showed significant differences
between active and inactive nose pokes (29, 30, 38–40th 2-AG
SA session). Two-way ANOVA of acquisition at the dose of
50µg/kg/infusion after rimonabant injection showed a signif-
icant main effect of active vs passive nose pokes (F1,9= 6.22;
p< 0.05) and of day (F2,8= 2.19; p< 0.05). LSD post hoc tests
showed significant differences between active and inactive nose
pokes (37–40th 2-AG SA session).
Figure 2B shows the mean number of responses during the last
three sessions of 2-AG SA at the dose of 50µg/kg/infusion (29–31st
2-AG SA session) and the effect of rimonabant pre-treatment (SR,
1 mg/kg ip, 30 min before each session) for two consecutive ses-
sions (32nd and 33rd 2-AG SA session). One-way ANOVA showed
a main effect of the different SA phases (F2,21= 9.91; p< 0.05).
LSD post hoc tests showed significant differences between groups.
Figure 3 shows that varying the injection dose of 2-AG
resulted in a classic inverted-U-shape dose–response curve.
One-way ANOVA showed that 2-AG maintained significantly
higher numbers of infusions per session (F3,8= 12.44; p< 0.01)
(Figure 3A) and higher rates of responding (F3,8= 45.75;
p< 0.001) (Figure 3B) than vehicle at the doses of 12.5, 25, and
50µg/kg/infusion. LSDpost hoc tests showed that the maximal rate
of responding (0.12± 0.09 response/s) and the number of injec-
tions per session (7± 1.19 injections/session) were maintained by
25µg/kg 2-AG/infusion. The highest 2-AG intake per session was
reached at a dose of 50µg/kg/injection (155± 0.40µg/session)
(Figure 3C).
MICRODIALYSIS STUDIES
Effect of 2-AG administration on dopamine transmission in the NAc
shell and core
Basal values of DA, expressed as fmoles/10 ml sample
(mean± SEM), were NAc shell 52± 5 (N = 19) and NAc core
54± 4 (N = 12).
Figure 4 shows that 2-AG (0.1–1.0 mg/kg iv) preferentially
stimulated the NAc shell with respect to the NAc core DA. The
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FIGURE 2 | 2-Arachidonoylglycerol self-administration (SA) behavior at
different 2-AG doses and effect of CB1 receptor blockade on SA.
(A) Number of responses (nose pokes) for 2-AG SA at varying 2-AG doses
(12.5, 25, and 50 µg/kg) and effect of SR-141716A (1mg/kg, 30 min before
sessions) on SA. Results are expressed as mean±SEM of cumulative nose
pokes in the active (circle) and inactive (triangle) nose pokes during each 1-h
daily session of 2-AG SA: 25µg/kg (1st–16th day); 12.5µg/kg (17th–23rd day);
and 50µg/kg (24th–43rd day), N =16. *p<0.05 vs inactive nose pokes;
#p<0.05 vs SR. ANOVA followed by LSD post hoc test. (B) Number of
responses during 2-AG SA and effect of SR-141716A on SA. Bars represent
the mean±SEM of the last three sessions under 2-AG SA (50µg/kg/inf)
condition (black bar) and under SR pre-treatment condition for two
consecutive session (SR, 1 mg/kg ip, 30 min before each session) (white bar).
*p<0.05 vs veh; #p<0.05 vs SR-50. ANOVA followed by LSD post hoc test.
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FIGURE 3 | Effect of varying injection dose on self-administration
(SA) of 2-AG. (A)Total number of injections of 2-AG (0, 12.5, 25, and
50µg/kg/inf), (B) overall rate of responding for 2-AG, and (C) total
2-AG intake as shown as a function of injection dose of drug (0,
12.5, 25, and 50µg/kg). Each point represents the mean±SEM of
the last three sessions under each 2-AG unit dose condition and
under vehicle condition, N =16. *p<0.05 post hoc comparison vs
veh (V).
NAc shell DA increase was observed only at the higher doses tested
(0.5 and 1.0 mg/kg iv) and was about 25% over basal value. One-
way ANOVA of the 0.5 mg/kg dose showed a main effect of group
(F12,48= 3.27; p< 0.001). Tukey post hoc tests revealed differences
at the 20 min sample with respect to basal value and to vehicle.
One-way ANOVA of the 1.0 mg/kg dose showed a main effect of
group (F12,48= 2.17;p< 0.05). Tukeypost hoc tests revealed differ-
ences at the 20 min sample with respect to vehicle and with respect
to basal value. Three way ANOVA of DA release of the NAc shell
and core implanted animals revealed a significant effect of dose
(F3,23= 4.9; p< 0.001) and a significant area × time interaction
(F12,276= 4.9; p< 0.05).
DISCUSSION
In the present study, we demonstrate for the first time that
the eCB 2-AG is SA by Sprague-Dawley rats and stimulates
DA transmission preferentially in the NAc shell as compared to
the core. Hence, 2-AG possesses behavioral and DA releasing
properties similar to those of food and drug rewards.
Initially, animals acquired 2-AG SA (25µg/kg/20µl infusion,
unit dose) in single daily 1 h FR1 sessions for 5 weeks, which was
then increased to FR2,under food restriction that maintained body
weights at stable levels throughout these studies. Active nose pokes
significantly increased over inactive nose pokes from the 6th SA
session (acquisition phase), but no significant increase of nose
pokes was observed under FR2. When 2-AG was replaced by vehi-
cle (25th SA session, extinction phase), the responding rate as well
as the number of injections slowly decreased. When the vehicle was
replaced once again with 2-AG, SA behavior immediately recov-
ered (reacquisition phase) (Figures 1A,C). In a second experiment,
the effect of dose of 2-AG (12.5, 25, 50µg/kg/20µl infusion, unit
dose) and the CB1 receptor-dependent SA behavior was assessed.
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FIGURE 4 | Effect of 2-AG injection on nucleus accumbens dialysate
dopamine. Effect of 2-AG (0.1, 0.5, and 1 mg/kg iv) on NAc shell (A) and
core (B) dialysate DA. Data are expressed as means (±SEM) of change in
DA extracellular levels expressed as a percentage of basal values. Solid
symbols: p<0.05 with respect to basal values; *p<0.05 vs veh group;
#p<0.05 vs 0.1 group.
Different doses of 2-AG showed a tendency toward a classic
inverted-U-shape dose–response curve, although non-significant
differences were observed between the 25µg/kg dose and the
other doses tested (Figure 3). The reinforcing effects of 2-AG
in SA behavior were fully blocked by the administration of the
CB1 receptor inverse agonist/antagonist SR-141716A (rimona-
bant, 1 mg/kg ip, 30 min before SA session) (Figure 2B). The
average number of responses during each 2-AG SA session, how-
ever, was lower in the present study than the responses (either
nose pokes or lever pressing) observed during SA studies using
other cannabinoids or other common drugs of abuse. Thus, rats
trained to SA WIN 55-212 (50, 56), nicotine (57, 58), cocaine (59,
60), or heroin (56, 61, 62) maintained higher rates of respond-
ing than what we observed for 2-AG SA. Nevertheless, our data
are in agreement with a previous study showing that 2-AG is
iv SA by non-human primates with either anandamide or nico-
tine SA history (40). Justinova et al. (40), however, observed that
in squirrel monkeys the rate of responding maintained by 2-AG
injections was similar to those observed in THC, anandamide,
methanandamide, or cocaine SA studies (39, 63–65). In contrast
with Justinova et al. (40), our experiments were carried out in
naive animals. Thus, our findings indicate that 2-AG serves as
an effective reinforcer and that its reinforcing properties are not
dependent on previous SA of other drug reinforcers.
A second group of naive rats was used to estimate the neuro-
chemical rewarding properties of 2-AG. Thus, 2-AG administered
iv at 0.5 and 1.0 mg/kg doses was able to stimulate extracellular
DA release preferentially in the NAc shell as compared to the core.
The increase of DA in the NAc shell was about 25% over basal
value, peaking at 20 min after the injection of 2-AG. DA stimula-
tion in this area was absent after the lowest dose tested (0.1 mg/kg
iv), and the DA levels were comparable to those after vehicle injec-
tions. Interestingly, the higher dose tested (1.0 mg/kg iv) elicited a
biphasic DA response with a second rise in DA levels 60 min after
2-AG injection. Notably, our data show for the first time that 2-AG
stimulates DA neurotransmission in the mesolimbic DA system.
This feature is a common characteristic of all the drugs abused
by human beings and it is believed to be crucial in the activation
of brain rewarding pathways (66, 67), to be an anticipatory mes-
sage for rewarding events (41) and to promote incentive learning
(68) specially the DA increase in the NAc shell (42). This 2-AG-
dependent increase of DA in the NAc shell most likely does not
depend on the direct activation of DA neurons in the VTA, but,
as in the case of THC and other cannabinoid agonists, is deter-
mined by the activation of CB1 receptors located on presynaptic
glutamatergic and/or GABAergic terminals onto VTA DA neurons
(69–71).
Previous studies have demonstrated that DA transmission
increases in a dose-dependent fashion after administration of
natural (THC), synthetic (WIN-55212), or endogenous (anan-
damide) cannabinoids and that this stimulation of DA in the NAc
shell peaks at about 50% over basal levels. The doses used in these
previous studies are comparable to those used in our study (49, 50,
52, 72) but they were accompanied by higher rates of SA behavior
(39, 63, 64). In the present study, we did not observe a similar
effect most likely due to the chemically unstable nature of 2-AG
that quickly converts to 1-AG (38, 73). This, together with MAGL
activity, could be responsible for the lack of high brain levels of
2-AG. Notably, in the present study, these properties of 2-AG were
carefully taken into consideration during the preparation of the
solutions for iv administration; 2AG content in administered solu-
tions was determined daily before microdialysis or SA sessions by
HPLC–MS/MS analysis.
Even though the rate of responding and DA stimulation were
lower for 2-AG than those observed after administration of com-
mon drugs of abuse, our study demonstrates that the eCB system
stimulation, via the mesolimbic DA system (microdialysis exper-
iments) or by 2-AG itself (SA experiments), encodes rewarding
events. The present microdialysis data, however, show that passive
administration as a single intravenous bolus of 2-AG increased
DA levels in the NAc shell at doses of 5–10-fold higher than the
2-AG intake reached by rats during SA behavior. A possible expla-
nation might be the sensitization of the effect of 2-AG on DA
transmission in the NAc shell of animals chronically exposed to
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2-AG during the acquisition of 2-AG SA. Further experiments of
SA coupled to microdialysis performed with the same experimen-
tal protocol previously published by our group (50) will serve to
directly correlate the preferential increase of DA in the NAc shell
to the 2-AG SA behavior observed in our experiments. On the
other hand, the results obtained in 2-AG SA experiments may be
also due to the food restriction regimen. Many studies show that
the reduction of body weight by 20–25% dramatically enhances
drug-induced SA (see (74) for review). Similarly, the suppression
of natural growth used in the present study, although not associ-
ated with loss of weight, may have increased the motivation for
2-AG, suggesting that 2-AG SA may not be crucial in standard
condition (e.g., ad libitum access to food). If so, the decrease of
active responding for 2-AG after the administration of rimona-
bant could be also due to the appetite suppression induced by this
drug (75).
Consistent with other studies (40, 52), the main significance of
our findings is not that 2-AG may pose a risk of abuse liability,
but that the activation of the eCB system together with the DA
system may potentiate the reinforcing effects or the abuse poten-
tial of many drugs of abuse, supporting the hypothesis that an
increase in eCB tone may be involved in drug-seeking behavior
(76). Recent studies show that the manipulation of eCB levels in
the brain can be selectively and successfully achieved by eCB clear-
ance inhibitors (2, 77–79). Altogether, the above evidence from
previous work, in conjunction with our current results, suggests
that the eCB system plays a role in reward and reinforcement that
makes it a good candidate as a therapeutic target in behavioral
disturbances of motivation and reward.
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